High-strength donor-specific antibody single-center cohort
10 evidence topics · 1 source
Objective
Transplantation objective
Location and study date
No evidence found.
Study design
Single-center experience
Eligibility criteria
Treatment
Timing of IdeS administration
Study outcomes
Rationale for using crossmatch conversion as the primary endpoint
Not applicable.
Statistical analysis description
Number of participants (Planned and analyzed)
Reported cohort
| Population | Participants |
|---|---|
| Transplant candidates | “7” |
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
Baseline sensitization and donor type
| Characteristic | Quoted value |
|---|---|
| Calculated panel-reactive antibody range | “cPRA98-100%” |
| Deceased donors | “5” |
| Living donors | “2” |
Efficacy results
High-strength donor-specific antibody: allograft function
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
High-strength donor-specific antibody: DSA rebound and rejection
Serious adverse events attributed to IdeS
Study limitations
Summary
This single-center report describes 7 participants, including 5 deceased-donor and 2 living-donor transplant recipients. All had functioning grafts at a median follow-up of 235 days, but 3 experienced antibody rebound and antibody-mediated rejection. The small series does not provide a randomized comparator. Its participants should not be assumed to be independent of other trial or follow-up publications without confirmation of participant overlap.